Theranexus (EPA:ALTHX) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
Theranexus

BRIEF

published on 11/13/2025 at 08:05, 21 days 22 hours ago

THX Pharma successfully completes its €7.8 million capital increase

Investors Capital Increase New Actions Neurological Diseases THX Pharma
PRESS RELEASE

published on 11/13/2025 at 08:00, 21 days 22 hours ago

THX Pharma announces the strong success of its approximately EUR 8 million capital increase to support its continued development and strengthen its financial structure
THX Pharma successfully raises €7.8 million through capital increase, issuing 4,356,804 new shares at €1.80 each. Existing shareholders show strong support. Subscription period ran from Oct 29 to Nov 7, 2025, for the fully funded roadmap

Shareholders Capital Increase New Shares Subscription Period THX Pharma
BRIEF

published on 11/07/2025 at 18:05, 27 days 12 hours ago

Theranexus: Publication of voting rights and shares as of October 31, 2025

Share Capital Voting Rights Biopharmaceutical Rare Diseases Theranexus
PRESS RELEASE

published on 10/23/2025 at 08:00, 1 month 12 days ago

THX Pharma announces the launch of a capital increase with preferential subscription rights of nearly EUR 8 million
THX Pharma launches a €8 million capital increase to fund rare neurological drug development, with 75.5% commitments secured. Batten-1 and TX01 to lead clinical and commercial endeavors with strategic shift to international markets. Investment opportunities for various tax schemes

Investment Capital Increase Drug Development Neurological Diseases THX Pharma
BRIEF

published on 10/14/2025 at 18:35, 1 month 21 days ago

THX Pharma and Exeltis Advance Toward Commercialization of TX01

Marketing Rare Diseases Exeltis TX01 THX Pharma
PRESS RELEASE

published on 10/14/2025 at 18:30, 1 month 21 days ago

THX PHARMA (THERANEXUS) AND EXELTIS ACHIEVE KEY MILESTONE TOWARDS THE COMMERCIALIZATION OF TX01
THX Pharma (Theranexus) and Exeltis achieve key milestone towards the commercialization of TX01 for rare neurological diseases, including Gaucher and Niemann-Pick type C. A pivotal step towards regulatory submission and global launch

Commercialization Neurological Diseases Exeltis TX01 THX Pharma
BRIEF

published on 09/29/2025 at 18:35, 2 months 5 days ago

THX Pharma: a strategic evolution towards international expansion

Growth Strategy Rare Diseases THX Pharma International Marketing Drugs TX01 And Batten-1
PRESS RELEASE

published on 09/29/2025 at 18:30, 2 months 5 days ago

Theranexus Becomes THX Pharma: A Strategic Evolution Toward the Commercialization of Its Medicines for Rare Diseases
THX Pharma (formerly Theranexus) announces strategic focus on regulatory approval, early access, and global commercialization of new drug candidates for rare neurological diseases

Regulatory Approval Commercialization Rare Neurological Diseases THX Pharma Early Access
BRIEF

published on 09/25/2025 at 18:05, 2 months 9 days ago

Theranexus publishes its financial results for the first half of 2025

Financial Results Cost Reduction Theranexus Batten-1 TX01
PRESS RELEASE

published on 09/25/2025 at 18:00, 2 months 9 days ago

THERANEXUS ANNOUNCES FIRST HALF 2025 FINANCIAL RESULTS
Theranexus announces first half 2025 financial results showing a decrease in operating expenses and a net loss of €1,072 K. Focus on developing flagship asset TX01 and advancing Batten-1

Financial Results Theranexus Batten-1 Operating Expenses TX01

1 2 ... 6

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 18 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 23 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 53 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 48 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 53 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 3 hours 22 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 2 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 27 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 38 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 42 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 53 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 8 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 8 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 52 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE